Daily Roundup | Hovilpri Wins FDA Approval & Biohaven Licenses BHV-1300 to Ono for $80M at Closing

<p>Friday, October 9 edition, released late Saturday, October 10.</p><p><br></p><p>FDA approved Hovilpri (pritelivir) for immunocompromised adults with stubborn herpes simplex lesions, but the oral drug is not yet available and is expected in the U.S. before the end of 2026. Biohaven agreed to license rights for parts of Asia to Phase 3 Graves&#39; disease candidate BHV-1300 to Ono for $80 million at closing, plus a separate conditional $20 million; the deal is not evidence of efficacy. Also: J&amp;J reports two-year Icotyde PASI 90 results without a long-term Sotyktu comparison, and Pennsylvania details GSK&#39;s $800 million-plus Upper Merion manufacturing expansion.</p><p><br></p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.</p>